Anti-EIF2C2 (AGO2) (Human) mAb

  • Applications
    • IP
    • RIP
    • WB
  • Target EIF2C2/AGO2
  • Host Species Mouse
  • Species Reactivities Human
  • Code # RN003M
  • Size 200 μl
  • Price
    $389.88
Specifications

Alternative Names

Eukaryotic translation initiationfactor 2C, subunit 2

Background

Eukaryotic translation initiation factor 2C, subunit 2 (EIF2C2; AGO2), is a member of the argonaute protein family. It is a core component of RNA-induced silencing complex (RISC). The EIF2C2 belonging to the human argonaute protein family possesses endonuclease activity and functions as a slicer in gene silencing pathways. It recognizes and cleaves target mRNA by RNA interference. In small interference RNA (siRNA) pathway, EIF2C2 forms a complex with EIF2C1 and siRNA, and in microRNA (miRNA) pathway, it binds EIF2C3 to miRNA. EIF2C2 expression is controlled by epidermal growth factor receptor and mitogen-activated protein kinase signaling in human breast cancer cell line.
  • Antibody Type:
    Monoclonal
  • Application:
    IP, RIP, WB
  • Clone Number:
    1B1-E2H5
  • Concentration:
    1 mg/mL
  • Conjugate:
    Unlabeled
  • Description:

    Monoclonal Antibody of 200 µl targeting EIF2C2/AGO2 for IP, RIP, WB.

  • Formulation:
    200 μg IgG in 200 μl volume of PBS containing 50% glycerol, pH 7.2. No preservative iscontained.
  • Gene ID (Human):
  • Gene ID (Mouse):
  • Host Species:
    Mouse
  • Immunogen:
    (180 amino acids. About terminal region of N) EIF2C2 partial-length recombinant
  • Isotype:
    IgG2a λ
  • Product Type:
    Antibody
  • Reactivity:
    This antibody reacts with humanEIF2C2 (~93.6 kDa) on Western blotting andImmunoprecipitation. Other species cross reactivity isconfirmed by Western blotting.
  • Research Area:
    Epigenetics
  • Short Description:

    EIF2C2/AGO2 Monoclonal Antibody.

  • Size:
    200 μl
  • Species Reactivity:
    Human
  • Storage Temperature:
    -20°C
  • Target:
    EIF2C2/AGO2
Citations
  1. Comincini S et al. microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells. Cancer Biol Ther. 14, 574-86 (2013),
  2. Degrauwe N et al. The RNA Binding Protein IMP2 Preserves Glioblastoma Stem Cells by Preventing let-7 Target Gene Silencing. Cell Rep. 15, 1634-47 (2016),
  3. Fukao A et al. MicroRNAs Trigger Dissociation of eIF4AI and eIF4AII from Target mRNAs in Humans. Mol Cell 56, 79-89 (2014),
  4. Marchesi N et al. Autophagy is modulated in human neuroblastoma cells through direct exposition to low frequency electromagnetic fields. J Cell Physiol. 229, 1776-86 (2014),
  5. Selitsky SR et al. Small tRNA-derived RNAs are increased and more abundant than microRNAs in chronic hepatitis B and C. Sci Rep. 5, 7675 (2015),
  6. Zhang LY et al. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis 34, 454-63 (2013)
  7. The RNA Binding Protein IMP2 Preserves Glioblastoma Stem Cells by Preventing let-7 Target Gene Silencing.
    Derauwe N et al. Cell Rep. (2016) 
  8. RNA Activation of the Vascular Endothelial Growth Factor Gene (VEGF) Promoter by Double-Stranded RNA and Hypoxia: Role of Noncoding VEGF Promoter Transcripts. Lopez P et al. Mol Cell Biol. 36, 1480-93 (2016)
References
  1. Adams, B. D., et al., Endocrinology 150, 14-23 (2009)
  2. Chi, S. W., et al., Nature 460, 479-486 (2009)
  3. Azuma-Mukai, A., et al., PNAS 105, 7964-7969 (2008)
  4. O’Carroll, D., et al., Genes & Dev. 21, 1999-2004 (2007)
  5. Liu, J., et al., Science 305, 1437-1441 (2004)